FDA's Mail-Order Abortion Drug Policy Is Dangerous and Should Be Blocked
Source: Elle Purnell. "Court Blocks FDA From Allowing Illegal, Deadly Abortion-By-Mail." May 2, 2026. thefederalist.com
The Gist
The author argues that allowing abortion pills to be mailed without requiring women to see a doctor first is dangerous and causes many more health problems than the government admits. She believes courts should stop this policy because it harms women and violates proper safety procedures.
Conclusion
The FDA's policy allowing mifepristone to be mailed without in-person doctor visits is dangerous and should be halted
Premises
- Mifepristone causes serious adverse effects at rates 22 times higher than reported on drug labels (10.93% vs. less than 0.5%)
- The policy resulted in nearly 1,000 illegal abortions per month in Louisiana alone
- Removing in-person examination requirements eliminates protections for women with ectopic pregnancies and those at risk of coercion
- The FDA itself admitted the policy changes had 'procedural deficits' and 'lack of adequate consideration'
- The 5th Circuit Court has found three times that the FDA's relaxation of safety guardrails 'likely lacked a basis in data and scientific literature'
- Louisiana documented paying thousands in Medicaid bills for women harmed by mifepristone under the new policy
Assumptions
- In-person doctor examinations provide meaningful safety protections
- The EPPC study methodology accurately reflects real-world adverse event rates
- Federal courts are appropriate venues for challenging FDA drug policies
- State governments have legitimate interests in regulating abortion drug distribution